Oxycodone hydrochloride with naloxone hydrochloride dihydrate
Brand: Targin®
PBAC's latest decision on Oxycodone hydrochloride with naloxone hydrochloride dihydrate: Recommended with restriction (2010). Considered for Chronic severe disabling pain not responding to non-narcotic analgesics.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
$45k/QALY
Range: $15k/QALY–$45k/QALY
Submissions
1
first 2010
Submissions
1
2010 → 2010
Eligible population
Chronic severe disabling pain not responding to non-narcotic analgesics.
Therapy area
Pain
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Bowel function index (BFI) score, Pain control
Key trials
OXN3401, OXN3001, OXN3006
Comparator
oxycodone controlled release, without prophylactic laxatives